Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALN-IL4R
- Development stage
- Unknown
- Lead developer
- Alnylam Pharmaceuticals
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Inhalation, Subcutaneous
01
Overview
ALN-IL4R (also known as REGN6191) is an investigational small interfering RNA (siRNA) therapeutic designed to silence the expression of the interleukin-4 receptor alpha (IL-4Rα) subunit. Developed through a strategic collaboration between Alnylam Pharmaceuticals and Regeneron Pharmaceuticals, the drug utilizes RNA interference (RNAi) to degrade the mRNA encoding IL-4Rα. Because IL-4Rα is a shared component of both the IL-4 and IL-13 receptor complexes, its knockdown effectively inhibits signaling of both cytokines, which are central drivers of Type 2 (Th2) inflammation. This mechanism is biologically analogous to the monoclonal antibody dupilumab, but by acting at the pre-translational level, ALN-IL4R may offer advantages such as localized delivery to the lungs via inhalation for respiratory conditions and a potentially longer duration of action, allowing for infrequent dosing schedules.
- Other names
- interleukin-4 receptor alpha small interfering RNAinterleukin4 receptor alpha small interfering RNAinterleukin 4 receptor alpha small interfering RNAIL-4Ra siRNAIL4Ra siRNAIL 4Ra siRNAIL4R-siRNAIL-4R-siRNAIL 4R-siRNA
02
Targets
IL4R (Interleukin-4 receptor alpha subunit)
Beyond the preview
Go deeper on ALN-IL4R.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALN-IL4R.